Aptamer-Drug Conjugate Platform
Oncology
Pre-clinicalActive
Key Facts
About Bioptamers
Founded in 2016, Bioptamers is a private, pre-revenue biotech focused on revolutionizing cancer treatment through personalized, aptamer-based drug delivery. The company's core technology is a microfluidic platform for selecting synthetic molecules (aptamers) that can precisely deliver chemical, radiation, or immunological therapies directly to tumors. While still in the pre-clinical development stage, Bioptamers aims to address the significant global oncology market by improving therapeutic outcomes and reducing off-target effects. Its strategy involves academic and industry collaborations to translate its platform into clinical candidates.
View full company profileTherapeutic Areas
Other Oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| mRNA Anticancer Vaccine | Sunshine Biopharma | Preclinical Research |
| Biosimilar Bevacizumab | Organon (2) | Phase 3 |
| Biosimilar Pembrolizumab | Organon (2) | Phase 3 |
| BCL-2 Inhibitor Program | Vincerx Pharma | Preclinical |
| KEAP1 Activator Program | Vividion Therapeutics | Phase 1 |
| Personalized Medicine Assays (Patient-Derived Explants) | Aurita Bioscience | Research-Use Only |
| CDK2-CyclinE1 & CDK2-CyclinA2 Assay | Aurora Biolabs | Commercial |
| POLQ & eIF4E Assay | Aurora Biolabs | Commercial |
| PKMYT1 & WEE1 Assay | Aurora Biolabs | Commercial |
| NTP42 | ATXA Therapeutics | Preclinical |
| Athebody® DARPins for pHLA-binding T-Cell Engagers | Athebio | Pre-clinical |
| Dual-Targeting CAR-T Programs | Factor Bioscience | Pre-clinical |